At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed May 5, 2026 at 09:14 ET
Alpha Tau Medical announced that an abstract on Alpha DaRT in combination with pembrolizumab for elderly patients with head and neck cancer has been accepted for a podium presentation at the AHNS International Conference (July 18-22, 2026). This marks a strategic milestone for the company's combination therapy program, building on prior monotherapy data.
- Abstract accepted for podium presentation at AHNS International Conference on Head and Neck Cancer (July 21, 2026)
- Study evaluates Alpha DaRT + pembrolizumab in elderly patients with locally advanced/metastatic HNSCC
- Complete top-line data to be presented; builds on prior monotherapy safety data
- Elderly HNSCC patients have limited treatment options, representing a significant unmet need
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access